19 -2 (26/1) 2019 — D.A. Egamberdieva — THE ROLE OF LIPID DISORDERS IN THE INITIATION OF CHRONIC KIDNEY DISEASE

THE ROLE OF LIPID DISORDERS IN THE INITIATION OF CHRONIC KIDNEY DISEASE

D.A. Egamberdieva Tashkent Pediatric Medical Institute.

Resume,

The initial assessment of the lipid profile serves mainly to diagnose hypercholesterolemia and / or hypertriglyceridemia and to eliminate potentially modifiable (secondary) causes of the progression of chronic kidney disease.

Significant relationships between lipid metabolism, daily proteinuria and indicators characterizing the functional state of the kidneys were identified.

Keywords: chronic kidney disease, lipid metabolism, glomerular filtration rate, obesity.

First page

75

Last page

77

For citation: D.A. Egamberdieva The role of lipid disorders in the initiation of chronic kidney disease//New Day in Medicine 2(26)2019 75-77 https://cutt.ly/CbvIoNu

List of References

  1. Смирнов А В. Клиническое и иропюстическое значение дис­липидемий у больных ХГН. /Автореферат дис. д.мл. СПб, 1997. 244 с.
  2. Колина И. Б. Влияние нарушений липидного обмена н тече­ние и пропит) хроническою гломерулонефрита с нефротическим синдромом. /Автореферат дисс… к.м.н М., 2002.
  3. Колина И. Б., Ставровская Е. В, Шилов Е. М. Липидного обмена на течение и прогаоз хроническою гломерулонефрита с нефротическим синдромом // Materia Medica. 2003, 37 (1): 31.
  4. Vaziri N. D. Dyslipidemiaof chronic renal failure: the nature, mechanisms, and potential consequences // Am J Physiol Ren Physiol. 2005; 290: F262-F272.
  5. Parfrey P. S., Foley R. N., Harnett J. D., Kent G. M., Murray D., Barre P. E. Outcome and risk factors of ischemic heart disease in chronic uremia // Kidney Int. 1996; 49: 1428-1434.
  6. Muntner P., He J., Astor B. C., Folsom A. R., Coresh J. Traditional and nontraditional risk factors predict согоп’ну heart disease in chronic kidney disease: results from the Atherosclerosis Risk in Communities Study // J Am Soc Nephrol. 2005; 16: 529-538.
  7. Wanner C., Krane V., Marz W. et al. Atorvastatin in patients with Type 2 diabetes mellitus undergoing hemodialysis // N. Engl. J. Med. 2005, 353 (3), 238-248.
  8. Fellstrom B. C., Jardine A. G., Schmieder R. E. et al. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis / / N. Engl. J. Med. 2009, 360 (14), 1395-1407.
  9. Jeppe Hagstrup Christensen, Erik Berg Schmidt. N-3 Polyunsaturated Fatty Acids, Lipids and Lipoproteins in End­stage Renal Disease //Clin Li pidology. 2011; 6 (5): 563-576.
  10. Saravanan P., Davidson N. C., Schmidt E. B., Calder P. C. Cardiovascular effects of marine omega-3 fatty acids // Lancet. 2011, 376 (9740), 540-550.
  11. De Caterina R. N-3 fatty acids in cardiovascular disease // N. Engl. J. Med. 2011, 364 (25), 2439-2450.
  12. Khajehdehi P. Lipid-lowering effect of polyunsaturated fatty acids in hemodialysis patients // J. Ren. Nutr. 2000, 10 (4), 191-195.
  13. Bowden R. G., Wilson R. L., Gentile M., Ounpraseuth S., Moore P., Leutholtz B. C. Effects of omega-3 fatty acid supplementation on vascular access thrombosis in polytetrafluorethylene grafts / / J. Ren. Nutr. 2007, 17 (2), 126-131.
  14. Svensson M., Schmidt E. B., Jorgensen K. A., Christensen J. H. N-3 fatty acids as secondary prevention against cardiovascular events in patients who undergo chronic hemodialysis: a randomized, placebo-controlled intervention trial // Clin. J. Am. Soc. Nephrol. 2006, 1 (4), 780-786.
  15. Kwak B., Mulhaupt F., Myit S., Mach F. Statins as a newly recognized type of immunomodulator // Nat Med. 2000, Dec; 6: 1399-1402.
  16. Palinski W. Immunomodulation: a new role for statins? // Nature Med. 2000; 12: 1311-1312.
  17. Rosenson R. S., Tangney C. C., Casey L. C. Inhibition of proinflammatory cytokine production by pravastatin // Lancet. 1999; 353: 983-984.

file

download